INT'L GROUP(SZ:000411)2023-04-28 16:00Financial Performance - The company's revenue for Q1 2023 was CNY 7,901,790,698, representing a 10.84% increase compared to CNY 7,129,176,805 in the same period last year[5]. - Net profit attributable to shareholders was CNY 68,312,123, a 43.67% increase from CNY 47,547,169 in the previous year[5]. - The net profit after deducting non-recurring gains and losses was CNY 65,655,538, up 49.06% from CNY 44,045,644 in the same period last year[5]. - The net profit for the first quarter of 2023 was CNY 113,580,698.34, an increase of 13.4% compared to CNY 99,818,774.94 in the same period last year[25]. - The total profit for the first quarter was CNY 157,369,392.65, up from CNY 140,877,321.23 in the same period last year, reflecting a growth of 11.5%[25]. - The total comprehensive income attributable to the parent company was CNY 68,230,967.65, compared to CNY 47,538,696.20 in the same period last year, indicating a growth of 43.4%[25]. - The operating profit for the first quarter was CNY 156,523,153.30, up from CNY 141,483,609.91, reflecting a growth of 10.4% year-over-year[25]. - The basic earnings per share increased to CNY 0.1859 from CNY 0.1591, representing a growth of 16.5%[26]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 15,075,534,086, a 14.52% increase from CNY 13,163,827,739 at the end of the previous year[5]. - The company's total assets as of March 31, 2023, amounted to CNY 15.08 billion, compared to CNY 13.16 billion at the beginning of the year, representing a growth of 14.5%[22]. - The total liabilities increased to approximately CNY 10.92 billion from CNY 9.28 billion, marking a rise of 17.7%[22]. - Shareholders' equity attributable to the parent company increased by 78.79% to CNY 3,725,446,871 from CNY 2,083,702,747 at the end of the previous year[5]. - The company's equity attributable to shareholders increased to approximately CNY 3.73 billion from CNY 2.08 billion, showing a growth of 79.5%[22]. Cash Flow - Cash flow from operating activities showed a slight improvement, with a net outflow of CNY 1,290,489,598, a 0.34% decrease in outflow compared to CNY 1,294,868,316 in the same period last year[5]. - The cash balance at the end of the period was CNY 1,817,731,762.64, reflecting a 41.17% increase from the previous period[10]. - The company reported a net cash inflow from financing activities of CNY 2,535,307,589.78, significantly higher than CNY 900,174,567.27 in the previous year[27]. - The net cash inflow from financing activities reached CNY 3,404,135,562.17, a 114.99% increase attributed to the rise in bank loans[10]. - The company experienced a decrease in credit impairment losses, which were CNY -18,524,261.56 compared to CNY -10,521,161.76 in the previous year[25]. Investments and Acquisitions - The company completed the acquisition of 100% of Yingtai Pharmaceutical's equity, increasing its ownership from 50%[14]. - The company plans to acquire 51% of Baishan Medical's equity, with the board approving the proposal on April 11, 2023[18]. - The cash outflow for the acquisition of fixed assets, intangible assets, and other long-term assets was CNY 43,005,891.29, representing a significant increase of 272.55% due to the investment in the Yingtai Pharmaceutical Valley operation center project[10]. - The cash outflow for other financing activities increased by 1,097.85% to CNY 254,639,409.65, mainly due to cash payments for acquiring minority stakes in subsidiaries[10]. Market Presence and Future Plans - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[5]. - The company received government subsidies amounting to CNY 3,172,001, contributing positively to its financial performance[6]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,518, with no preferred shareholders[12]. - Zhejiang International Trade Group Co., Ltd. held 24.03% of the shares, making it the largest shareholder[12].